2023
P105: Measuring clinically relevant change in apathy symptoms in ADMET 2
Tuma S, Herrmann N, Perin J, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, CraG S, Levey A, Shade D, Mintzer J, Lanctôt K. P105: Measuring clinically relevant change in apathy symptoms in ADMET 2. International Psychogeriatrics 2023, 35: 126-127. DOI: 10.1017/s1041610223002569.Peer-Reviewed Original ResearchImpression of ChangeChange scoresMeasure clinically relevant changesNPI apathy scoreEffect sizeClinical impression of changeMinimal clinically significant improvementClinical Global Impression of ChangeSpearman correlationClinical Global ImpressionClinically significant improvementSix-month visitGlobal Impression of ChangePsychosocial interventionsClinically relevant changesApathy symptomsAssessment ScaleAssessment Change ScoreMann-Whitney U testComplete dataWorsened groupParticipantsApathyNo changeTreatment trials
2022
Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
Lanctôt K, Perin J, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.066932.Peer-Reviewed Original ResearchHeterogeneity of responseAlzheimer's diseaseAD patientsBaseline anxietyPlacebo-controlled clinical trialApathetic AD patientsDaily Living ScaleCommon neuropsychiatric symptomsLow functional capacityLower functional capabilityNPI apathy scoreLower baseline anxietyAD medicationsDifference of changesNeuropsychiatric InventoryNeuropsychiatric symptomsApathetic patientsClinical trialsMonth visitTreatment outcomesEffect differencesSignificant apathyLiving ScaleApathy scoresFunctional capacity